Back

drs. U.V.V. (Frank ) Kreek

drs. U.V.V. (Frank ) Kreek

Full Professor

Show full profile

Research Output (516)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy:The ODYSSEY CHOICE II Study

Stroes Erik, Guyton John R, Lepor Norman, Civeira Fernando, Gaudet Daniel, Watts Gerald F, Baccara-Dinet Marie T, Lecorps Guillaume, Manvelian Garen, Farnier Michel, , Visseren FLJ 13 Sep 2016, In: Journal of the American Heart Association. 5

Bisphosphonates for cardiovascular risk reduction:A systematic review and meta-analysis

Kranenburg Guido, Bartstra Jonas W., Weijmans Maaike, de Jong Pim A., Mali Willem P., Verhaar Harald J., Visseren Frank L J, Spiering Wilko 1 Sep 2016, In: Atherosclerosis. 252 , p. 106-115 10 p.

Abdominal fat and blood pressure in healthy young children

Jansen Maria A C, Uiterwaal Cuno S P M, Visseren Frank L J, van der Ent Cornelis K., Grobbee Diederick E., Dalmeijer Geertje W. Sep 2016, In: Journal of Hypertension. 34 , p. 1796-803 8 p.

Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study

Krikke Maaike, Tesselaar Kiki, Arends Joop E, Drylewicz Julia, Otto Sigrid A, van Lelyveld Steven F L, Visseren Frank J L, Hoepelman Andy I M Sep 2016, In: Infectious Diseases and Therapy. 5 , p. 389–404

Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease

Lafeber Melvin, Webster Ruth, Visseren Frank L J, Bots Michiel L., Grobbee Diederick E., Spiering W., Rodgers Anthony 1 Aug 2016, In: European Journal of Preventive Cardiology. 23 , p. 1289-1297 9 p.

HDL cholesterol as a residual risk factor for vascular events and all cause mortality in patients with type 2 diabetes

Sharif Shahnam, Van Der Graaf Yolanda, Nathoe Hendrik M., de Valk Harold W., Visseren Frank L J, Westerink Jan 1 Aug 2016, In: Diabetes Care. 39 , p. 1424-1430 7 p.

Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease:the SMART study

Gerritsen Karin G, Falke Lucas L, van Vuuren Stefan H, Leeuwis Jan W, Broekhuizen Roel, Nguyen Tri Q, de Borst Gert Jan, Nathoe Hendrik M, Verhaar Marianne C, Kok Robbert J, Goldschmeding Roel, Visseren Frank L, Aug 2016, In: Growth factors. 34 , p. 149-58 10 p.

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease

Bots Sophie H, van der Graaf Yolanda, Nathoe Hendrik M W , de Borst Gert Jan, Kappelle Jaap L, Visseren Frank L J, Westerink Jan, 19 Jul 2016, In: Cardiovascular Diabetology [E]. 15

Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer:Treating the right patients based on individualized treatment effect prediction

van Kruijsdijk R. C M, Visseren F. L J, Boni L., Groen H. J M, Dingemans A. M C, Aerts J. G J V, van der Graaf Y., Ardizzoni A., Smit E. F. 1 Jul 2016, In: Annals of Oncology. 27 , p. 1280-1286 7 p.

Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus

van der Leeuw Joep, Beulens Joline W J, van Dieren Susan, Schalkwijk Casper G., Glatz Jan F C, Hofker Marten H., Monique Verschuren W. M., Boer Jolanda M A, van der Graaf Yolanda, Visseren Frank L J, Peelen Linda M., van der Schouw Yvonne T. 1 Jun 2016, In: Journal of the American Heart Association. 5

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not